|
CLINICAL PIPELINE
Pain Therapeutics is a biopharmaceutical company that develops novel drugs for pain management and hematology/oncology. We have three investigational drug candidates in clinical programs. Remoxy and PTI-202 are proprietary, abuse-deterrent forms of opioid drugs. Oxytrex is a novel, next-generation painkiller that potentially offers less physical dependence than currently marketed opioid painkillers. Our early-stage drugs include a novel radio-labeled monoclonal antibody to treat metastatic melanoma, a deadly form of skin cancer. We are also working on a new treatment for patients with hemophilia, a rare blood disorder. The FDA has not yet evaluated the merits, safety or efficacy of our drug candidates.
PIPELINE STATUS
| Drug Candidate |
Indication |
Phase |
Commercial Rights |
| Remoxy |
Moderate/severe chronic pain |
III |
King Pharmaceuticals |
| Oxytrex |
Moderate/severe chronic pain |
III |
Pain Therapeutics, Inc. |
| PTI-202 |
Moderate/severe chronic pain |
I |
King Pharmaceuticals |
| Monoclonal Antibody |
Metastatic melanoma |
I |
Pain Therapeutics, Inc. |
| Factor IX Replacement |
Hemophilia |
Pre-clinical |
Pain Therapeutics, Inc. |
|
|